Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71205-327

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 71205-327). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line chart displaying the percentage of patients with systolic blood pressure below 140 mmHg (% SBP <140) on the vertical axis, plotted against baseline systolic blood pressure (SBP) in mmHg on the horizontal axis. Four lines represent treatments: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, showing the relationship between baseline SBP and treatment effect.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph showing the percentage of patients achieving diastolic blood pressure under 90 mmHg (% DBP<90) versus baseline diastolic blood pressure (DBP) in mmHg. The graph compares four treatment groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, each represented by different markers and lines.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph depicting the percentage of systolic blood pressure (SBP) below 130 mmHg versus baseline SBP (mmHg). It compares four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, showing the efficacy in lowering SBP at various baseline levels.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph showing percentage of patients with diastolic blood pressure (DBP) less than 80 mmHg on the vertical axis and baseline DBP in mmHg on the horizontal axis. Four data sets are plotted: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, each represented by distinct markers. The graph compares the effect of these treatments across a range of baseline DBP values.*
FDA Label Image

71205-327-30 (Valsartan Hctz 80 12 5mg 90s Baddi)

71205-327-30 (Valsartan Hctz 80 12 5mg 90s Baddi)
Label for Valsartan HCTZ 80 mg / 12.5 mg film-coated tablets by Proficient Rx LP, containing 30 tablets. The label includes the active ingredients Valsartan USP 80 mg and Hydrochlorothiazide USP 12.5 mg, with tablets described as light orange, oval-shaped, biconvex, and debossed with "L16". Manufactured by Macleods Pharmaceuticals Ltd., India.*
FDA Label Image

Valsartan (Valsartan)

Valsartan (Valsartan)
Chemical structure of valsartan, the active ingredient in Valsartan and Hydrochlorothiazide tablets.*
FDA Label Image

Hctz-str (Valsartn Hctz Str)

Hctz-str (Valsartn Hctz Str)
Chemical structure diagram of valsartan and hydrochlorothiazide showing molecular components including a benzene ring with chloro, sulfonamide, and other functional groups consistent with these active ingredients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.